Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for BLRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
March 31, 2026 16.67M
December 31, 2025 18.20M
September 30, 2025 19.53M
June 30, 2025 20.07M
March 31, 2025 20.86M
December 31, 2024 13.46M
September 30, 2024 8.505M
June 30, 2024 13.98M
March 31, 2024 13.06M
December 31, 2023 13.22M
September 30, 2023 13.13M
June 30, 2023 21.05M
March 31, 2023 39.11M
December 31, 2022 50.84M
September 30, 2022 55.52M
June 30, 2022 56.57M
March 31, 2022 63.41M
December 31, 2021 68.09M
September 30, 2021 70.90M
June 30, 2021 73.89M
March 31, 2021 64.65M
December 31, 2020 22.03M
September 30, 2020 24.81M
June 30, 2020 29.23M
March 31, 2020 28.51M
Date Value
December 31, 2019 33.38M
September 30, 2019 39.20M
June 30, 2019 41.78M
March 31, 2019 45.89M
December 31, 2018 41.32M
September 30, 2018 40.58M
June 30, 2018 46.19M
March 31, 2018 49.02M
December 31, 2017 52.88M
September 30, 2017 58.96M
June 30, 2017 57.38M
March 31, 2017 35.63M
December 31, 2016 34.99M
September 30, 2016 38.62M
June 30, 2016 42.56M
March 31, 2016 46.00M
December 31, 2015 47.61M
September 30, 2015 50.67M
June 30, 2015 51.82M
March 31, 2015 54.19M
December 31, 2014 31.79M
September 30, 2014 26.87M
June 30, 2014 29.32M
March 31, 2014 32.34M
December 31, 2013 11.72M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
XTL Biopharmaceuticals Ltd. --
Kamada Ltd. 269.56M
Can-Fite BioPharma Ltd. --
Galmed Pharmaceuticals Ltd. 13.95M
Revium Recovery, Inc. 18.10M

Shareholders Equity (Quarterly) Related Metrics